Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis

Abstract

Summary What is known and objective The FDA has provided recommendations for aripiprazole use in CYP2D6 poor metabolizers (PMs); however, PMs make up <1% of the Asian population and no recommendation has been provided for intermediate metabolizers (IMs), who comprise a considerable proportion of the Asian population (64%‐70% occurrence of CYP2D6*10). This study aimed to investigate the characteristics of aripiprazole metabolism in IMs and other phenotypes by conducting the first meta‐analysis of the association among CYP2D6 phenotypes and aripiprazole pharmacokinetics (PK). Methods We searched four electronic databases for studies published through February 2018, investigating the association between aripiprazole and CYP2D6 gene polymorphisms. Gene polymorphism information was extracted, and CYP2D6 phenotypes were determined according to a unified classification standard. The associations between three aripiprazole PK‐related outcomes and CYP2D6 phenotype were analysed. Meta‐analyses were used to compare ultra‐rapid metabolizers (UMs) vs extensive metabolizers (EMs), EMs vs IMs and IMs vs poor metabolizers (PMs) for each outcome. The aripiprazole serum concentration funnel plot and the Egger's and Begg's tests were used to assess publication bias. Results and discussion Altogether, 10 studies were included in this analysis (n = 649). Aripiprazole serum concentration differed significantly between EMs and IMs (EM vs IM pooled SMD: −0.383; 95% CI: −0.735 to −0.031, P = 0.03 < 0.05), but not between IMs and PMs (IM vs PM pooled SMD: −0.425; 95% CI: −0.933 to 0.082, P = 0.10 > 0.05). However, aripiprazole plus dehydroaripiprazole serum level did not significantly differ among EMs, IMs and PMs (EM vs IM pooled SMD: −0.285; 95% CI: −0.724 to 0.154, P = 0.20 > 0.05; IM vs PM pooled SMD: −0.302; 95%CI: −0.810 to 0.205, P = 0.24 > 0.05). Overall, aripiprazole serum level and the sum level of aripiprazole plus dehydroaripiprazole in different phenotypes followed the trend UMs < EMs < IMs < PMs, whereas dehydroaripiprazole serum level followed the trend UMs < EMs > IMs > PMs. What is new and conclusion Aripiprazole serum concentration differed significantly between EMs and IMs, but not between PMs. Whether this has clinical significance requires further evaluation by randomized trials.

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan

“…In this study, the serum aripiprazole concentrations in inpatients and outpatients diagnosed with schizophrenia and treated with aripiprazole were analyzed, and the interaction of concentration with patient variables was studied. CYP2D6 polymorphism and various phenotypes of metabolizers influence the serum concentration of aripiprazole, 11 and similar rates of elimination have been reported in Han Chinese and white participants. 12 The time required to achieve steady-state serum drug concentrations is approximately 14 days.…”

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis

“…and one decreased-function allele (*9, *10, *17, etc.) were classified as IMs; those who had one functional allele (*1, *2, *33, *35) were classified as EMs; and those carrying two functional alleles were classified as UMs [ 13 , 15 ].…”

Determination of eugenitin in mouse blood by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study

“…Pharmacokinetic, was a science that uses mathematical analysis to deal with the dynamic processes of drugs in the body [4][5][6][7][8]. Until now, there were no reports about the pharmacokinetics of eugenitin in biological fluids.…”